| Jaspreet Singh, MD | |
|
445 Charles H Dimmock Pkwy, Ste 100, Colonial Heights, VA 23834-2970 | |
| (804) 520-1764 | |
| (866) 781-3220 |
| Full Name | Jaspreet Singh |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 19 Years |
| Location | 445 Charles H Dimmock Pkwy, Colonial Heights, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942495312 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Family Care, Inc. - Tucson | Tucson, AZ | Hospice |
| Southside Regional Medical Center | Petersburg, VA | Hospital |
| Cjw Medical Center | Richmond, VA | Hospital |
| John Randolph Medical Center | Hopewell, VA | Hospital |
| Southern Virginia Regional Medical Center | Emporia, VA | Hospital |
| Southampton Memorial Hospital | Franklin, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| James River Cardiology Llc | 0941499594 | 24 |
News Archive
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.
Yale School of Medicine has launched a state-of-the-art database funded in part by the National Library of Medicine, called the Canary Database, containing scientific evidence about how animal disease events can be an early warning system for emerging human diseases.
Results from a 10-year study of children and adolescents who underwent a common weight loss operation to treat severe obesity show they safely have long-lasting major weight loss and improvement of their obesity-related medical problems without stunting their growth in height. The study, involving the longest known follow-up of pediatric patients after laparoscopic sleeve gastrectomy, is published online by the Journal of the American College of Surgeons ahead of print.
› Verified 8 days ago
| Entity Name | Chippenham & Johnston-willis Hospitals, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366689747 PECOS PAC ID: 9032105010 Enrollment ID: O20040831000405 |
News Archive
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.
Yale School of Medicine has launched a state-of-the-art database funded in part by the National Library of Medicine, called the Canary Database, containing scientific evidence about how animal disease events can be an early warning system for emerging human diseases.
Results from a 10-year study of children and adolescents who underwent a common weight loss operation to treat severe obesity show they safely have long-lasting major weight loss and improvement of their obesity-related medical problems without stunting their growth in height. The study, involving the longest known follow-up of pediatric patients after laparoscopic sleeve gastrectomy, is published online by the Journal of the American College of Surgeons ahead of print.
› Verified 8 days ago
| Entity Name | Columbia-hca John Randolph, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952762650 PECOS PAC ID: 0244206753 Enrollment ID: O20040907000809 |
News Archive
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.
Yale School of Medicine has launched a state-of-the-art database funded in part by the National Library of Medicine, called the Canary Database, containing scientific evidence about how animal disease events can be an early warning system for emerging human diseases.
Results from a 10-year study of children and adolescents who underwent a common weight loss operation to treat severe obesity show they safely have long-lasting major weight loss and improvement of their obesity-related medical problems without stunting their growth in height. The study, involving the longest known follow-up of pediatric patients after laparoscopic sleeve gastrectomy, is published online by the Journal of the American College of Surgeons ahead of print.
› Verified 8 days ago
| Entity Name | James River Cardiology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407157647 PECOS PAC ID: 0941499594 Enrollment ID: O20110112000790 |
News Archive
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.
Yale School of Medicine has launched a state-of-the-art database funded in part by the National Library of Medicine, called the Canary Database, containing scientific evidence about how animal disease events can be an early warning system for emerging human diseases.
Results from a 10-year study of children and adolescents who underwent a common weight loss operation to treat severe obesity show they safely have long-lasting major weight loss and improvement of their obesity-related medical problems without stunting their growth in height. The study, involving the longest known follow-up of pediatric patients after laparoscopic sleeve gastrectomy, is published online by the Journal of the American College of Surgeons ahead of print.
› Verified 8 days ago
| Entity Name | Bon Secours Medical Group Richmond Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477112225 PECOS PAC ID: 8022440056 Enrollment ID: O20191113002170 |
News Archive
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.
Yale School of Medicine has launched a state-of-the-art database funded in part by the National Library of Medicine, called the Canary Database, containing scientific evidence about how animal disease events can be an early warning system for emerging human diseases.
Results from a 10-year study of children and adolescents who underwent a common weight loss operation to treat severe obesity show they safely have long-lasting major weight loss and improvement of their obesity-related medical problems without stunting their growth in height. The study, involving the longest known follow-up of pediatric patients after laparoscopic sleeve gastrectomy, is published online by the Journal of the American College of Surgeons ahead of print.
› Verified 8 days ago
| Entity Name | Aligned Interventional Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881473247 PECOS PAC ID: 7911358759 Enrollment ID: O20240105003126 |
News Archive
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.
Yale School of Medicine has launched a state-of-the-art database funded in part by the National Library of Medicine, called the Canary Database, containing scientific evidence about how animal disease events can be an early warning system for emerging human diseases.
Results from a 10-year study of children and adolescents who underwent a common weight loss operation to treat severe obesity show they safely have long-lasting major weight loss and improvement of their obesity-related medical problems without stunting their growth in height. The study, involving the longest known follow-up of pediatric patients after laparoscopic sleeve gastrectomy, is published online by the Journal of the American College of Surgeons ahead of print.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jaspreet Singh, MD 445 Charles H Dimmock Pkwy, Ste 100, Colonial Heights, VA 23834-2970 Ph: (804) 520-1764 | Jaspreet Singh, MD 445 Charles H Dimmock Pkwy, Ste 100, Colonial Heights, VA 23834-2970 Ph: (804) 520-1764 |
News Archive
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.
Yale School of Medicine has launched a state-of-the-art database funded in part by the National Library of Medicine, called the Canary Database, containing scientific evidence about how animal disease events can be an early warning system for emerging human diseases.
Results from a 10-year study of children and adolescents who underwent a common weight loss operation to treat severe obesity show they safely have long-lasting major weight loss and improvement of their obesity-related medical problems without stunting their growth in height. The study, involving the longest known follow-up of pediatric patients after laparoscopic sleeve gastrectomy, is published online by the Journal of the American College of Surgeons ahead of print.
› Verified 8 days ago
Steven R Frelier, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 430 Claremont Ct, Suite 213, Colonial Heights, VA 23834 Phone: 804-520-2626 Fax: 804-520-0626 | |
Irshad Ahmed, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2801 Boulevard, Suite B, Colonial Heights, VA 23834 Phone: 804-524-0524 Fax: 804-524-0520 | |
Dr. George Eigbire, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 445 Charles H Dimmock Pkwy Ste 100, Colonial Heights, VA 23834 Phone: 804-520-1764 Fax: 804-616-4221 | |
Peter J Riley, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 445 Charles H Dimmock Pkwy Ste 100, Colonial Heights, VA 23834 Phone: 804-520-1764 Fax: 804-616-4221 | |
Ambreen Sajjad Siddiquie, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1260 Temple Ave, Colonial Heights, VA 23834 Phone: 804-518-2597 Fax: 804-518-2598 | |
Dr. Kochurani Cherian Puthumana, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 215 Temple Ave, Colonial Heights, VA 23834 Phone: 804-526-8640 Fax: 804-526-4321 | |
Sarah Shahabuddin, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 130 Temple Lake Dr, Suite 5, Colonial Heights, VA 23834 Phone: 804-526-3450 Fax: 804-520-1809 |